Trial Profile
Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 25 Mar 2013 Istradefylline has been approved in Japan according to a media release from Kyowa Hakko Kirin.
- 24 May 2012 Actual patient number 308 added as reported by ClinicalTrials.gov.